[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69842225D1 - Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet - Google Patents

Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet

Info

Publication number
DE69842225D1
DE69842225D1 DE69842225T DE69842225T DE69842225D1 DE 69842225 D1 DE69842225 D1 DE 69842225D1 DE 69842225 T DE69842225 T DE 69842225T DE 69842225 T DE69842225 T DE 69842225T DE 69842225 D1 DE69842225 D1 DE 69842225D1
Authority
DE
Germany
Prior art keywords
crsp
nucleic acid
cysteine
antibody
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69842225T
Other languages
English (en)
Inventor
Sean A Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27485904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69842225(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69842225D1 publication Critical patent/DE69842225D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
DE69842225T 1997-04-16 1998-04-16 Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet Expired - Lifetime DE69842225D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84370497A 1997-04-16 1997-04-16
US84289897A 1997-04-17 1997-04-17
US7158998P 1998-01-15 1998-01-15
US980298A 1998-01-20 1998-01-20

Publications (1)

Publication Number Publication Date
DE69842225D1 true DE69842225D1 (de) 2011-05-26

Family

ID=27485904

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69842225T Expired - Lifetime DE69842225D1 (de) 1997-04-16 1998-04-16 Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE69837085T Expired - Lifetime DE69837085T3 (de) 1997-04-16 1998-04-16 Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69837085T Expired - Lifetime DE69837085T3 (de) 1997-04-16 1998-04-16 Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen

Country Status (11)

Country Link
EP (3) EP1852507B1 (de)
JP (4) JP2001524824A (de)
AT (2) ATE353964T1 (de)
AU (2) AU7137398A (de)
CA (1) CA2288430C (de)
CY (1) CY1107629T1 (de)
DE (2) DE69842225D1 (de)
DK (1) DK0975755T3 (de)
ES (1) ES2285768T5 (de)
PT (1) PT975755E (de)
WO (1) WO1998046755A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
ES2359401T3 (es) * 1997-08-01 2011-05-23 Merck Serono Biodevelopment ESTs 5¿PARA PROTEÍNAS SECRETADAS, EXPRESADAS EN DIVERSOS TEJIDOS.
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
CN1197965C (zh) * 1998-10-26 2005-04-20 诺维信公司 在丝状真菌细胞内构建和筛选目的dna文库
EP1161445A2 (de) * 1999-03-05 2001-12-12 Millennium Pharmaceuticals, Inc. Menschliche dickkopf-verwandte proteine und nukleinsäuremoleküle und deren verwendungen
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
CN1402784A (zh) * 1999-11-19 2003-03-12 久光制药株式会社 细胞增殖抑制蛋白质、多核苷酸、与多核苷酸对应的反义核苷酸,以及细胞增殖抑制剂、癌症诊断试剂、癌症治疗剂和用于基因治疗的组合物
JP2003528300A (ja) * 2000-02-24 2003-09-24 オックスフォード グリコサイエンセス（ユーケー） リミテッド 神経精神及び神経障害におけるｄｐｉ−６、推定上の治療ターゲットおよびバイオマーカー
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
WO2005049797A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
WO2005049640A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US7867699B2 (en) 2004-03-23 2011-01-11 Wyeth Method of synthesizing and purifying Dkk proteins and Dkk proteins obtained thereby
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US7465585B1 (en) 2006-04-10 2008-12-16 The Burnham Institute Compositions and methods for inhibiting cell migration
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06501679A (ja) 1990-07-10 1994-02-24 スミスクライン・ビーチャム・コーポレイション オキサミド
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU9076191A (en) 1990-11-21 1992-06-25 Massachusetts Institute Of Technology Mice having beta 2 microglobulin gene disruption
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1820858B1 (de) 1991-03-01 2009-08-12 Dyax Corporation Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE256738T1 (de) 1992-10-30 2004-01-15 Gen Hospital Corp Ein neues zellzyklus kontrollprotein
EP1262564A3 (de) 1993-01-07 2004-03-31 Sequenom, Inc. Dns-Sequenzierung durch Massenspektrometrie
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
JP2001507227A (ja) * 1996-12-20 2001-06-05 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 小脳および胚に特異的なタンパク質
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
EP0975755A1 (de) 2000-02-02
ES2285768T5 (es) 2011-12-22
DE69837085T2 (de) 2007-11-22
ATE353964T1 (de) 2007-03-15
EP0975755B2 (de) 2011-08-03
CA2288430C (en) 2013-04-09
JP2001524824A (ja) 2001-12-04
DE69837085D1 (de) 2007-03-29
EP2298899A3 (de) 2011-08-24
CA2288430A1 (en) 1998-10-22
AU7137398A (en) 1998-11-11
JP2010011853A (ja) 2010-01-21
DK0975755T3 (da) 2007-06-11
EP1852507B1 (de) 2011-04-13
EP0975755B1 (de) 2007-02-14
WO1998046755A1 (en) 1998-10-22
EP2298899A2 (de) 2011-03-23
ATE505543T1 (de) 2011-04-15
JP2010227110A (ja) 2010-10-14
PT975755E (pt) 2007-06-26
EP0975755B9 (de) 2007-08-29
EP1852507A1 (de) 2007-11-07
ES2285768T3 (es) 2007-11-16
JP2006166917A (ja) 2006-06-29
AU2009227915A1 (en) 2009-11-12
CY1107629T1 (el) 2013-06-19
DE69837085T3 (de) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1107629T1 (el) Πρωτεïνη crsp (πλουσιες σε κυστεïνη εκκρινομενες πρωτεïνες) μορια νουκλεϊνικου οξεως που τις κωδικοποιουν και χρησεις τους
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
EP1009752A4 (de) Neue moleküle aus der familieder tango-77-ähnlichen proteine und ihre verewendungen.
WO2002070652A3 (en) Novel molecules of the card-related protein family and uses thereof
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
WO2002044354A3 (en) Molecules of the card-related protein family and uses thereof
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2001000826A3 (en) Novel molecules of the card-related protein family and uses thereof
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
WO1999054437A3 (en) Novel molecules of the t125-related protein family and uses thereof
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2002061049A3 (en) Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
WO2001030971A3 (en) Novel molecules and the card-related protein family and uses thereof
WO2003029434A3 (en) Novel molecules of the hkid-1-related protein family and uses thereof
WO2001077151A3 (en) Fdrg proteins and nucleic acid molecules and uses therefor
WO2002085939A8 (en) Novel molecules of the card-related protein family and uses thereof
WO2002038767A3 (en) G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2000018890A3 (en) Protein phosphatase molecules and uses therefor
WO1999062943A3 (en) Novel molecules of the aip-related protein family and uses thereof
WO2001083523A3 (en) Stmst protein and nucleic acid molecules and uses therefor
WO2001059065A3 (en) Novel molecules of the card-related protein family and uses thereof